Clearside Biomedical shares fall 54.04% premarket after filing for Chapter 11 bankruptcy in the US.

Clearside Biomedical’s shares plummeted 54.04% in premarket trading following the company’s filing for Chapter 11 bankruptcy in the U.S. Court documents revealed estimated assets of $1 million–$10 million and liabilities of $50 million–$100 million, signaling severe financial distress. The bankruptcy filing, which underscores operational challenges and liquidity constraints, aligns with the stock’s precipitous decline. As a biopharmaceutical firm developing therapies for eye diseases, the filing raises immediate concerns about its ability to fund ongoing clinical trials, including its Phase 2b program for CLS-AX, or sustain operations. The move reflects a critical deterioration in the company’s financial position, directly driving the sharp premarket sell-off.